Overview
DIA’s Canadian Pharmacovigilance and Risk Management Strategies Conference is the premier place to hear from expert pharmaceutical, biotechnology, and regulatory personnel about Global Regulatory Guidance Document updates (pharmacovigilance, risk management, and drug safety), gain new perspectives from the Inspectorate, and discuss patient support programs and PV responsibilities. Join in on an exclusive session with the Canadian regulator, touching on a host of current topics including the management of Canada Vigilance Adverse Reaction Online Database duplicate safety reports.
On-Demand Complimentary Webinar
Plain Language Labeling for Over-the-Counter Drugs: Implementing Health Canada’s Guidance for Industry
On-Demand
This webinar will review Health Canada’s requirements for Plain Language Labeling for over-the-counter medicines. Presenters will walk through key recently finalized and revised guidance documents to help industry comply with these requirements and identify strategies to help industry add Drug Facts Tables to packaging while minimizing the need for packaging increases. Register today!
DIA's Canadian Health Care Content Roundup
NEW! This year DIA's Canadian Pharmacovigilance and Risk Management Conference will be co-located with the DIA Canadian Annual Meeting. Maximize your education and time by attending both!
While our conference is currently in development, check out last year’s program to see what’s in store!
View Program.
Featured
Who should attend?
Professionals involved in:
- Advertising and Promotion
- Biotechnology
- Clinical Data Management/eClinical
- CMC
- Combination Products
- Clinical Safety and Pharmacovigilance
- Clinical Research
- Medical Devices and Diagnostics
- Pharmacology
- Regulatory Affairs
Learning objectives
At the conclusion of this activity, participants should be able to:
- Describe the current Canadian regulatory framework for pharmacovigilance
- Examine current Pharmacovigilance issues facing Marketing Authorization Holders in Canada
- Discuss proposed changes to Vanessa’s Law
- Identify strategies for implementing benefit-risk analyses and risk management plans
Program Committee
-
Rita Cassola, RPh • Executive Director PV
Certus PV Services Inc, Canada -
Marcia Bailey, BSN, MHS, RN • Safety Evaluation & Risk Management Scientific Director
GSK, Canada -
Colin D'Cunha, MD, MHS, FRCPC • Director, Global Medical Affairs
Apotex Inc., Canada -
Ljubica Ivanisevic, PhD • Scientific Evaluator
Health Canada, Canada -
Marc Poitras, PhD, MBA • Scientific Manager, Marketed Pharmaceuticals and Medical Devices Bureau
Health Canada, Canada
Contact us
Questions?
On-Demand Complimentary Webinar | September 18
Plain Language Labeling for Over-the-Counter Drugs: Implementing Health Canada’s Guidance for Industry
Co-Located Meeting | Oct. 17-18
DIA Annual Canadian Meeting
